FY 2025 Guidance The Group is introducing guidance for FY 2025 under U.S. GAAP. Comparisons for certain guidance elements to FY 2024 financial results under U.S. GAAP are provided in the February 20, 2025 Investor Presentation. NR is equivalent under U.S. GAAP and IFRS with minimal changes in the other guidance elements presented below. Guidance assumes no material change in exchange rates for key currencies compared with FY 2024 average rates, notably USD/GBP and USD/EUR. Guidance also assumes no material change to Medicaid eligibility policy and/or other changes to Federal funding levels due to executive actions. 2 FY 2025 Net Revenue (NR) $955m to $1,025m (-17% at the mid-point vs. FY 2024) SUBLOCADE NR $725m to $765m (-1% at the mid-point vs. FY 2024) OPVEE NR $10m to $15m SUBOXONE Film Market Share Accelerated NR decline in FY 2025 reflecting increased generic competitive activity and the potential impact from a fifth buprenorphine/ naloxone sublingual film generic in the U.S. market Adjusted Gross Margin Low to mid-80s % range Adjusted SG&A ($525m) to ($535m) Adjusted R&D ($85m) to ($90m) Adjusted Operating Profit $185m to $225m
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.